Search for: "In Re Adoption of EMA" Results 1 - 15 of 15
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
22 Apr 2016, 12:18 pm by Tom Lamb
Going back to the April 2016 EMA press release for what will happen then: The PRAC recommendations will then be forwarded to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which will adopt a final opinion. [read post]
28 Jul 2018, 4:07 pm by Lawrence B. Ebert
These recommendations have recently been re-evaluated by EMA's Committee for Medicinal Products for Human Use (CHMP), and confirmed the final opinion of the European Medicines Agency. [read post]
27 Jun 2011, 7:18 pm
We're not there yet, but it's gonna be the future soon. [read post]
2 Oct 2020, 4:27 pm by Eugene Volokh
The case is In re Certified Questions; I doubt I'll be able to analyze it in detail, but here is the court's summary of the opinions: [1.] [read post]
4 Jan 2019, 9:16 pm
The application in question was made pursuant to Article 263 TFEU for annulment of an act adopted by the Commission removing Elotuzumab from the Community Register of orphan medicinal products for human use and/or of a possible act adopted by the Commission or the EMA determining that Elotuzumab no longer met the criteria for designation as an orphan medicinal product when the marketing authorisation was granted for the medicinal product Empliciti (Elotuzumab) under… [read post]
5 Apr 2021, 6:36 pm by Jim Walker
NCLH has adopted a policy of “Mandatory Vaccinations on Initial Voyages” which states that: “All guests and crew must be fully vaccinated, at least 2 weeks prior to departure, in order to board. [read post]
18 Feb 2022, 4:14 pm by INFORRM
Re|Shaping Policies for Creativity – Addressing culture as a global public good The UNESCO Global Report “is the third edition of a series designed to monitor the implementation of the 2005 Convention on the Protection and Promotion of the Diversity of Cultural Expressions. [read post]
To that end, the Roadmap: a) singles out a number of criteria to be used in determining when to relax the restrictions; b) lays down operational principles designed to guarantee a coherent action on the part of the Member States; c) indicates a number of precautions that must adopted while repealing the current measures and d) formulates specific recommendations on how to proceed. [read post]
9 Aug 2012, 4:00 pm by Rebecca Tushnet
  Because we’re supposed to? [read post]
22 May 2021, 2:07 am by Kluwer Patent blogger
” You’re the editor of the Wolters Kluwer publication ‘Patent Protection for Second Medical Uses’. [read post]
9 Jul 2011, 11:37 pm by Josh Blackman
The title of this post captures a current blogosphere disagreement between Dave Kopel and Doug Berman regarding the interpretation of the Second Amendment in Ezell v. [read post]